PTAB Relies on Priority Analysis in a Related Proceeding in Denying IPR

Jan 17, 2018

Reading Time : 1 min

ESET argued that the claims of the ’086 Patent are obvious in view of several combinations of prior art references, primarily relying on a reference titled Proof-Carrying Code (“Necula”). In the 01444 proceeding, Finjan argued that FireEye had failed to establish that Necula antedated the priority date of the ’086 Patent. ESET argued that the ’086 Patent was not entitled to a priority date antedating Necula because none of the patents or patent applications from which the ’086 Patent claimed benefit disclosed the specific limitations claimed by the ’086 Patent. The PTAB stated that it had analyzed the claims of the ’926 Patent in the 00145 proceeding and sided with the patent owner, finding that the disclosure provided sufficient written-description support. The PTAB noted that the claims of the ’086 Patent at issue contained limitations that were nearly identical to those of the ’926 Patent. For example, Claim 1 of the ’926 Patent recites “appending a representation of the retrieved Downloadable security profile data to the incoming Downloadable, to generate and appended Downloadable,” and Claim 1 of the ’086 Patent recites the same limitation without the words “retrieved” and “incoming”.

Given that the claim language of the ’926 Patent was nearly identical to that of the ’086 Patent, the PTAB held that the ’086 Patent shares essentially the same disclosure as the ’926 Patent. The PTAB also noted that the ’086 Patent incorporates the ’926 Patent by reference. The PTAB therefore denied ESET’s petition and joinder motion.

ESET, LLC v. Finjan, Inc., IPR2017-01969, Paper No. 8 (PTAB January 9, 2018).

Share This Insight

Previous Entries

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.